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Oxidative stressDiabetes is a recognized risk factor for cardiovascular diseases and heart failure. Diabetic cardiovascular
dysfunction also underscores the development of diabetic retinopathy, nephropathy and neuropathy. Despite
the broad availability of antidiabetic therapy, glycemic control still remains amajor challenge in themanagement
of diabetic patients. Hyperglycemia triggers formation of advanced glycosylation end products (AGEs), activates
protein kinase C, enhances polyol pathway, glucose autoxidation,which coupledwith elevated levels of free fatty
acids, and leptin have been implicated in increased generation of superoxide anion by mitochondria, NADPH
oxidases and xanthine oxidoreductase in diabetic vasculature and myocardium. Superoxide anion interacts
with nitric oxide forming the potent toxin peroxynitrite via diffusion limited reaction, which in concert
with other oxidants triggers activation of stress kinases, endoplasmic reticulum stress, mitochondrial and
poly(ADP-ribose) polymerase 1-dependent cell death, dysregulates autophagy/mitophagy, inactivates key
proteins involved in myocardial calcium handling/contractility and antioxidant defense, activates matrix
metalloproteinases and redox-dependent pro-inflammatory transcription factors (e.g. nuclear factor kappaB)
promoting inflammation, AGEs formation, eventually culminating in myocardial dysfunction, remodeling and
heart failure. Understanding the complex interplay of oxidative/nitrosative stress with pro-inflammatory,
metabolic and cell death pathways is critical to devise novel targeted therapies for diabetic cardiomyopathy,
which will be overviewed in this brief synopsis. This article is part of a Special Issue entitled: Autophagy and
protein quality control in cardiometabolic diseases.
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Incidence of metabolic diseases, especially of obesity and type II dia-
betes is constantly growing worldwide. Diabetes is a well-recognized
risk factor for cardiovascular diseases and heart failure [1]. The term of
diabetic cardiomyopathy has been introduced by Rubler et al. back in
1972 [2]. Later the Framingham Heart Study has also demonstrated
that the occurrence of heart failure in male and female diabetics is
twice and five times more common, respectively, compared to age-
matched control subjects [3]. Similar cross-sectional studies confirmed
increased risk for heart failure development in diabetics, even when
corrected for other confounding variables such as coronary artery dis-
ease, hypercholesterolemia, hypertension, and obesity [4–7]. Notably,
the higher occurrence of biventricular dysfunction and cardiomyopathy
in diabetics is also suggestive of the fact that diabetes is an independent
risk factor or cause of cardiomyopathy [7–9].
Although it is established that multiple factors may collectively con-
tribute to the development and progression of diabetic cardiomyopathy
(e.g. hyperglycemia, insulin resistance, increased fatty acid metabolism,
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mation, remodelling andfibrosis), the exactmolecularmechanisms that
trigger and fuel thesemajor pathological processes are not entirely clear
(Fig. 1).
Accumulating recent evidence suggests that the complex interplay of
oxidative, nitrosative and nitrative stress [10–12] with major proinflam-
matory,metabolic [13] and cell death pathways [14–17] play an essential
role in the development of complex biochemical [18,19], mechanical,
and structural alterations associated with diabetic cardiomyopathy
[8,20,21], which will be overviewed in this brief synopsis.
2. Oxidative, nitrosative and nitrative stress in
diabetic cardiomyopathy
Oxidative and subsequent nitrosative damage of the myocardium
and vasculature have been described as major primary mechanisms
leading to pathologic alterations associatedwith diabetic cardiovascular
complications [22–29]. Factors such as hyperglycemia, glucose autoxi-
dation, accumulation of advanced glycosylation end products (AGEs),
enhanced receptor for advanced glycation end product (RAGE) and
angiotensin II receptor type 1 (AT1R) signaling, elevated levels of free
fatty acids and leptin, have been reported to contribute to increased pro-
duction of reactive oxygen and nitrogen species production (ROS/RNS)
in diabetic vessels and myocardium [22,24], among others. In spite of
the broad availability of antidiabetic therapy, glycemic control still
remains a major challenge in the management of diabetic patients [30].
Inadequate glycemic control likely accounts for the high prevalence of
diabetic complications, since high glucose or fluctuating glucose levels
[31] can induce acute oxidative stress that might be a critical factor in
the initiation of pathologic alterations eventually leading todevelopment
of diabetic cardiomyopathy [16,24]. Oxidative proteinmodifications playLiver
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Fig. 1. Interplay of hyperglycemia and peripheral metabolism in cardiometabolic syndrome in
metabolic consequences) or directly enhance diabetes-associated inflammation and ROS gene
complications. AT II rec, angiotensin II receptor type 1; CNS, central nervous system; PMNs, poa pivotal role in the development of diabetic myocardial dysfunction.
Oxidation of proteins involved in contractility, excitation–contraction
coupling, protein folding, antioxidant defence, metabolism (mainly
fatty acid and glucose), and Ca2+ handling have been reported in diabet-
ic hearts (see Table 1). Oxidative modification may result in potentially
harmful events including dissociation of catalytic subunits of enzymes,
local or global unfolding, aggregation or fragmentation. Proteins can
be oxidized directly by ROS, or by products of secondary oxidation
reactions formed during lipid peroxidation (e.g., malondialdehyde or
4-hydroxynonenal). Moreover, oxidative protein modifications may
also occur by reactive sugars in glycation or glycoxidation reactions [32].
Depending on the amount of modified proteins and the extent of oxida-
tion, different degradation mechanisms are activated. Mildly oxidized
proteins are broken down primarily by the proteasome, while heavily
oxidized proteins (potentially forming aggregates) are degraded by
the endosomal–lysosomal pathway thereafter [33]. Thus, an increase
in oxidative stress might produce substrates that fuel autophagic pro-
tein degradation, at least in the first stages of oxidative injury [34]. In
addition, certain proteins involved in autophagosome formation and
maturation (Atg4, LC3-II) require oxidative posttranslational modifica-
tions [35,36], thus, activity of these proteins are also strongly influenced
by their redox status [35]. However, the accumulation of oxidized and
nitrated proteins and lipids suggest abrogated autophagic processes in
diabetic cardiomyopathy thatmay significantly contribute tomyocardi-
al dysfunction.
Several cellular and subcellular sources were described that may
account for enhanced ROS production in diabetic cardiovascular system
and at other sites of diabetic complications (e.g. in the retina and
kidneys) (Fig. 2). This list includes nicotinamide adenine dinucleotide
phosphate oxidases (NADPH oxidases) [37–39], xanthine oxidase/
oxidoreductase (XO) [40,41], enzymes of the arachidonic acid cascadeularsystem
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Table 1
Oxidative and nitrative modifications of key myocardial proteins in diabetic cardiomyopathy.
Modified protein Modification Function Reference
CaMK-II Oxidation Singalling [45]
Protein disulfide isomerase Oxidation Protein folding [140]
Complexes I, III, and V Oxidation ATP synthesis [141]
mtHSP70, mitofilin Oxidation Mitochondrial protein import [141]
Alpha-enolase Oxidation/nitration Glycolysis [142]
Succinyl-CoA:3-oxoacid CoA transferase Nitration Ketone body metabolism [143–145]
Creatine kinase Nitration Muscle contraction [144]
Peroxiredoxin 3 Nitration Antioxidant defense [144]
Complex I (24 kDa subunit) Nitration ATP synthesis [144]
Acyl coenzyme A thioester hydrolase Oxidation Fatty acid metabolism [146]
Acetyl-CoA acetyl transferase Oxidation Fatty acid metabolism [146]
Acyl CoA dehydrogenase Oxidation Fatty acid metabolism [146]
3-ketoacyl-CoA thiolase Oxidation Fatty acid metabolism [146]
Enoyl-CoA hydratase Oxidation Fatty acid metabolism [146]
Heart-type fatty acid-binding protein Oxidation Fatty acid metabolism [146]
Glutathione Peroxidase-1 Oxidation Antioxidant defense [146]
Glutathione-S-Transferase Oxidation Antioxidant defense [146]
Superoxide Dismutase-2 Oxidation Antioxidant defense [146]
Peroxiredoxin-1 Oxidation Antioxidant defense [146]
Peroxiredoxin-2 Oxidation Antioxidant defense [146]
Peroxiredoxin-3 Oxidation Antioxidant defense [146]
Peroxiredoxin-6 Oxidation Antioxidant defense [146]
Ryanodine receptors (RyR2) Oxidation Excitation–contraction [147]
SERCA2a Oxidation Ca2+ handling [148]
Myosin heavy chain alpha and beta Oxidation Contraction [149]
GAPDH Nitrosylation Glycolysis [150]
Caspase-3 Nitrosylation Apoptosis [150]
Connexin43 Nitration Cell–cell communication [151]
ATP synthase subunits Nitration ATP synthesis [84]
thioredoxin-1 Nitration Antioxidant defense [152,153]
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the uncoupled nitric oxide synthases (NOS) [10], and themitochondrial
respiratory chain [24]. Among these, increased mitochondrial ROS
generation initially was considered to represent the primary source of
high glucose-induced oxidative stress in several tissues and cell types,
including cardiomyocytes [24,37,42] and endothelial cells [43,44]. Luo
et al. recently showed, that mitochondrial oxidants significantly
contribute to the oxidation of the multifunctional enzyme, Ca2+/
calmodulin-dependent protein kinase II (CaMKII) [45]. Diabetic mice
treatedwith amitochondria-targeted antioxidant, MitoTEMPO, showed
reduced levels of oxidized-CaMKII, subsequently with preserved
heart rates, and improved survival after myocardial infarction [45].
Mitoquinone, a mitochondrially targeted ubiquinone that can act as an
antioxidant, also improves cardiac dysfunction [46] and activates
autophagy in an Nrf2-dependent manner in a non-cardiac system
[47], suggesting an interaction between mitochondrial redox balance
and protein quality control mechanisms, such as autophagy.
There is also evidence for increased production of ROS from non-
mitochondrial sources. NADPH oxidases (NOX) are unique enzymes
that may be responsible for large amounts of superoxide and hydrogen
peroxide (H2O2) production under various pathological conditions.
Activity or expression of various NOX isoenzymes (that are involved
in superoxide or H2O2 generation), has been found to be significantly
higher in the heart with metabolic derangements such as diabetes
[37–39,48,49] and hypercholesterolemia [50]. The increased activity
and expression of NOX4 in the diabetic heart [49] is therapeutically tar-
getable, and NOX4 inhibitors are indeed in preclinical development for
various cardiovascular indications [51]. Diabetes induced increase in
NADPH activity is further accentuated by the increased production of
NADPH by glucose-6-phosphate dehydrogenase, as it was described in
the heart and aorta of Zucker diabetic fatty rats [52]. Elevated concen-
tration of hydrogen peroxide has been shown to modulate autophagy
by several mechanisms. For example, H2O2, activates the LKB1/AMPK
pathwaywhich leads to inhibition of themTORC1 complex and induced
autophagy [53]. NOX4-mediated production of hydrogen peroxide also
induces autophagy in humanumbilical vein endothelial cells [54] and incardiomyocytes [55] after induction of endoplasmic reticulum stress.
Although, it is plausible that excessive amounts of ROS might incapaci-
tate certain players of autophagy. VascularNADPHoxidase is also an im-
portant downstream target of angiotensin II, which has been proposed
to play a pivotal pathological role in the development and progression
of diabetic cardiovascular [56–59] and other diabetic complications.
This is supported by convincing evidence obtained from preclinical
rodent models of STZ (streptozotocin)-induced type 1 diabetes, as
well as from human myocardial biopsy specimens, suggesting that the
renin–angiotensin system is up-regulated in diabetes and angiotensin
II locally through AT1R, which is overexpressed in diabetic hearts or in
cardiomyocytes exposed to high glucose, importantly contributes to
the development of diabetic cardiomyopathy [38,57–60]. The beneficial
effects of AT1R blockade in diabetic hearts involve, but are not limited to,
the attenuation of myocardial NADPH oxidase-dependent (such as
p47phox) ROS generation, inflammation, cell death, fibrosis, and con-
tractile dysfunction [57–60]. AT1 receptor blockade also prevents
glucose-induced cardiac dysfunction directly in ventricular myocytes
via attenuating the AT1-NADPH oxidase signaling [61]. Consistently
with the important pathological role of NADPH oxidases-derived ROS
generation in diabetic hearts, apocynin (a putative non-specific
NADPHoxidase inhibitor) not only attenuated the enhanced superoxide
generation in diabetic hearts, but also improved the diabetes-associated
cardiac dysfunction in type I diabetic mice [39].
Increased activation of another ROS generating enzyme, the XO, has
also been shown in different organs [62] of diabetic rats or mice, in-
cluding in the heart [41]. Conversely, inhibition of XO by allopurinol
significantly attenuated most pathological features of diabetic cardio-
myopathy (e.g. myocardial ROS/RNS generation, iNOS expression, cell
death, and fibrosis) and improved both systolic and diastolic dysfunc-
tions in type I diabetic mouse [41] or rat [63] hearts. Importantly,
there is also current evidence, coupled with numerous previous studies
[40], for the beneficial cardiac effects of allopurinol in humans [64].
Rekhraj at al. recently described, that in patient with ischemic heart
disease, high dose off allopurinol was capable to reduce left ventricular
muscle mass and improve the symptoms of the disease [65].
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is also impaired in diabetic hearts promoting impaired vasorelaxation and enhanced atherogenesis eventually facilitating increased cardiovascular inflammation, and lipid deposition in
vessels and myocardium, functional ischemia and enhanced cardiac injury.
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reduced nitric oxide (NO) availability in diabetic tissues. Different
mechanisms have been proposed to be responsible for the diabetes-
induced dysfunction of NO production, bioavailability and/or signaling.
A generally accepted mechanism is the alterations in nitric oxide
synthases (NOS), particularly in its endothelial isoform (eNOS), function
[10,66]. The composition of the eNOS complex is critical for the relative
formation of NO or superoxide. The mechanisms by which eNOS dys-
function develops remain elusive, however, a decrease in the dimer to
monomer eNOS ratio within the myocardium of diabetic animals has
been reported [67]. Monomerization i.e. uncoupling of NOS results in
increased oxidative stress and decreased NO bioavailability (since
uncoupled NOS generates superoxide anion instead of NO), which has
been implicated in the pathophysiology of numerous cardiovascular
diseases. Accordingly, eNOS uncoupling has also been reported in
diabetic hearts, while administration of the tetrahydrobiopterin precur-
sor, sepiapterin inhibited uncoupling of NOS and improved LV function[68]. Similarly, ascorbic acid or N-acetyl-cystein is also capable to
increase BH4/BH2 ratio and prevent NOS uncoupling in the diabetic
heart [69].
In addition to uncoupling the major cardiac NOS isoforms, iNOS and
eNOS expression has been shown to be increased (particularly iNOS) in
the diabetic hearts [37,38,70,71]. The increase in NOS expression in
the diabetic heart is associated with an increase in lipid peroxidation
and 3-nitrotyrosine formation (marker of peroxynitrite generation
and nitrative stress), which might be related to the uncoupled and
monomer state of the enzyme, which most likely produces superoxide
instead of NO, as well as triggers the formation of peroxynitrite. Inter-
estingly, peroxynitrite itself also causes NOS un-coupling by selectively
targeting and disrupting caveolae–NOS interaction [72].
The rapid diffusion-limited reaction of superoxide with NO
indeed forms peroxynitrite, a very strong cytotoxic oxidant, which
attacks and damages various biomolecules via multiple mechanisms
[10]. In agreement with these, inhibition of NOS activity (by L-NAME
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gesting that the increased production of superoxide and peroxynitrite
rather than NO is a major contributor of suppressed contractile perfor-
mance in diabetes [39,66,73,74]. NO and peroxynitrite has a very com-
plex relation to autophagy. Nitric oxide donors have been shown to
decreased autophagy in HeLa cells, which has been confirmed by the
overexpression of eNOS [75]. Although, LPS-induced up-regulation of
NOS izoenzymes were followed by an accelerated autophagy in HL-1
cells and in mice [76]. Since LPS induces the production of not only NO,
but peroxynitrite, these seemingly opposing results can be explained. It
is further evidenced by other studies, where peroxynitrite exerted inhib-
itory effects on autophagy. For example, peroxynitrite induced autopha-
gy in endothelial cells and increased LC3-II protein [77]. These data well
demonstrate that sub-physiological NO levels and nitrosative/nitrative
stress which are characteristic to diabetes, might facilitate autophagic
processes in the heart, however, direct observations are yet to be
made. Peroxynitrite formation and consequent protein nitration
(nitrative stress) have been suggested to play a central role in the devel-
opment of cardiovascular dysfunction associated with diabetes, as well
as in the development of diabetic retinopathy, nephropathy and neurop-
athy. Peroxynitrite in hearts not only promotes apoptotic or necrotic cell
death in cardiomyocytes and endothelial cells via activation of stress
signaling pathways (e.g. mitogen activated protein kinases (MAPKs)
and poly ADP ribose polymerase 1 (PARP-1)-dependent pathways), but
also induces nitration and consequent inactivation of key proteins in-
volved in intracellular calcium cycling, energy homeostasis, antioxidant
defense, and myocardial contractility (see Table 2.) [10]. Peroxynitrite,
in concert with other oxidant may also activate matrix metalloprotein-
ases (MMPs) in the failing hearts to promote pathological remodeling
[23,37,78] and may impair the NO-soluble guanylate cyclase signaling
pathway rendering NO to unable to activate its primary protectiveTable 2
Main therapeutic approaches and targets in diabetic cardiomyopathy.
Therapeutic target Approach
Oxidative, nitrosative, nitrative stress
NADPH oxidases Enzyme inhibition
Apocynin, (VAS2870 or GKT137831
AT-1 receptor antagonist
Xanthine oxidase Enzyme inhibition
Allopurinol
eNOS Uncoupling inhibitors
L-Arginine
Tetrahydrobiopterin
IGF-1
iNOS Enzyme inhibition
L-NIL
Peroxynitrite Decomposition catalysts
MnTMPyP
FP15
Mitochondria oxidative stress MitoTEMPO
NRF2 Activators
Sulforafan
DH404
ROCK Enzyme inhibition
Fasudil
Cell death pathways—Autophagy/Mitophagy, Apoptosis, PARP-dependent cell death
p38 MAPK Enzyme inhibition
SB 239063
PARP Enzyme inhibition
PJ34
3-aminobenzamide
AMPK activation Metformin
GLP-1 GLP-1 agonists, DPP-4 inhibitors
Inflammation
Cytokine expression (TNFα, IL1β, TGFβ) p38 MAPK inhibition
AT-1 receptor antagonist
Endocannabinoid system CB1 antagonistsignaling machinery [79,80]. Furthermore, peroxynitrite decomposition
catalysts have been shown to restore the normal contractile phenotype
of high glucose treated cardiomyocytes and attenuate cardiac dysfunc-
tion in diabetic hearts [74]. The importance of peroxynitrite has also
been shown in diabetic patients. Increased serum and/or vascular
3-nitrotyrosine levels were positively correlated with increased blood
pressure, and or endothelial dysfunction in diabetic patients [29,81].
The persistently increased myocardial oxidative and nitrative stress
in diabetic hearts eventually also leads to dysfunction of important an-
tioxidant defense mechanisms [10] (e.g. inactivation of important anti-
oxidant enzymes such as superoxide dismutases and catalase, depletion
of endogenous antioxidants (e.g. metallothionein, glutathione) [37,
82–84]) and dysregulation of important redox-dependent transcription
factors (e.g. NFE2L2 nuclear factor, erythroid 2-like 2 (Nrf2)) [85,86],
among others. Increased oxidative and nitrative stress in diabetes may
also promote oxidation and/or nitration of various insulin receptors in
peripheral tissues, which may contribute to the development of insulin
resistance [87].
Hyperglycemia and/or hyperglycemia-induced ROShas been report-
ed to increase accumulation of products of nonenzymatic glycation/
oxidation of proteins/lipids (AGE) and enhanced the expression of
their receptor (RAGE) in cardiovascular tissues, which thought to play
a key role in the development and progression of cardiovascular compli-
cations of diabetes [88,89]. Accumulation of AGEs and increased expres-
sion of RAGE have been associated with diabetes-induced dysfunction
and structural alterations in hearts of type 1 diabetic rodents [88,89].
Furthermore, in diabetic heart failure patients with reduced LV ejection
fraction, the accumulation of AGEs and fibrosis appear to contribute
to the increased diastolic stiffness, but not in patients with normal LV
ejection fraction, where the increased cardiomyocyte resting tension is
responsible for this phenomenon [90].Reference Potential effect on autophagy
) [39,154] Potential inhibitors of autophagy [55,155]
[61] Potential inhibitors of autophagy [156]
[40,41,63,64] No information
[157] Potentially inhibits autophagy by NO [75,158]
[68] Potentially inhibits autophagy by NO [159]
[160] Potential inhibitor of autophagy [161]
[162,163] No information in the literature.
[28] Potential inhibitors of autophagy [77]
[164]
[45] No information in the literature.
[165] Potential autophagy inducer [166]
[167]
[168] Potential autophagy inducer [169]
[170] Potential inhibitors of autophagy [76]
[118]
[171] Potential inhibitors of autophagy [172]
[104] Potential autophagy inducer [99]
[173–177] Potential autophagy inducers [178]
[122] Potential inhibitors of autophagy [76]
[57] Potential inhibitors of autophagy [156]
[38] Potential inhibitors of autophagy [139]
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diabetic cardiomyopathy
It has extensively been documented that increased oxidative and
nitrative stress in diabetic hearts may trigger activation of stress signal-
ling pathways facilitating apoptosis in cardiomyocytes and endothelial
cells [14]. However, recent evidence also suggests that in addition to
apoptosis, other processes such as autophagy, mitophagy and PARP-
dependent cell death pathways may also play an important role in
controlling the cell demise during the course of cardiovascular disease
[91] and diabetic cardiomyopathy [17], which will be discussed in the
following part.
Autophagy is a cellular housekeeping process that is essential for
removal of damaged or unwanted organelles, protein and lipid
aggregates. It is a dynamic process which is tightly regulated by the
availability of nutrients and the metabolic balance of the cell, and func-
tional autophagy is indispensable for cellular survival in low-energy
conditions [92]. Since in diabetes, where oxidative stress, protein- and
lipid oxidation are elevated and cellular energy balance is disturbed,
functional autophagy might have even higher importance in the main-
tenance of cardiac cellular integrity. In the heart, constitutive autophagy
is a homeostatic mechanism for maintaining cardiac structure and
function [93], while disruption of autophagy leads to heart failure [94].
Interestingly, in healthy animals, autophagy seems to be higher in
males than in females suggesting that themale heart has amajor consti-
tutive autophagy [95]. This gender difference may elucidate the obser-
vation of the Framingham Heart Study showing markedly increased
occurrence of diabetic cardiomyopathy in females [3,96]. Autophagy is
suppressed at high glucose concentrations, such as present in diabetes,
whichmight be associated with the development of diabetic cardiomy-
opathy [97]. In addition, the diabetic heart is characterized by excessive
fatty acid uptake and oxidation, resulting in accumulation of toxic lipid
intermediates (long-chain acyl-CoA, diacylglycerol, ceramides), known
as lipotoxicity. Cardiac lipotoxicity contributes to insulin resistance,
impairment of mitochondrial function, cardiomyocyte hypertrophy,
and apoptosis, whichmayultimately lead to left ventricular remodelling
of the heart [98].
Elevated oxidative stress, apoptosis, inflammation, and ER stress by
increased production of monocyte chemoatractic protein-1 (MCP-1) is
suspected to contribute to the disruption of cardiac autophagy in diabe-
tes [97,99–101] Several upstream signalling pathways of autophagy are
altered in diabetes ormetabolic syndrome aswell [102]. Themammalian
target of rapamycin (mTOR) pathway, a negative regulator of autophagy
is blunted in obese, hyperlipidemic rats fed a high cholesterol-high
fructose diet showing most characteristics of type II diabetes [103].
Also, activity of AMP-activated protein kinase (AMPK) is reduced in
high glucose conditions, leading to disturbed autophagy [104]. Although
the majority of reports agree on the attenuation of the autophagy in
diabetes, not all studies are equivocal (possibly due to the different ex-
perimental models used). For example, in a fructose-fed mouse model,
induction of autophagy has been described [105], and milk fat-based
chow blunted cardiac autophagy and facilitated cardiomyopathy more
efficiently than a lard-based chow [106]. Further complicating the pic-
ture is the discrepancy that oxidative stress is elevated in diabetes,
which is supposed to induce autophagy, however, themajority of studies
evidence quite the opposite. This phenomenon and the lack of any direct
evidence from diabetic patients warrant further investigations on
the status of cardiac autophagy in disease models relevant to human
pathological conditions.
Aiming to restore pathological cardiac consequences of diabetes
modulation of autophagy has been attempted by different tools. Chronic
activation of AMPK (therefore autophagy) bymetformin or overexpres-
sion of ATG7 reduced cardiomyocyte apoptosis, cardiac fibrosis, and im-
proved myocardial functions in streptozotocin (STZ)-induced diabetic
mice [104]. Overexpression of hem oxygenase-1 in STZ-treated mice
also induced autophagy, reduced oxidative stress and inflammationand prevented cardiac dysfunction [97]. In a recent report, inhibition
of mTOR signalling by the overexpression of PRAS40 prevented the
development of cardiomyopathy in high-fat diet-fed mice [107].
Furthermore, it was also demonstrated that disturbed autophagy
undermine the benefit of exercise in protection against high-fat-diet-
induced glucose intolerance [108]. However, a few papers disagree
with this conclusion. Suppression of autophagy prevented apoptosis in
neonatal and adult cardiomyocytes in extremely high glucose condi-
tions resembling to uncontrolled diabetes [109]. Furthermore, overex-
pression of beclin-1, an inducer of autophagy, worsened cardiac
function and enhanced apoptosis in STZ-treated mice, while cardiac
damage by STZ-induced diabetes was blunted in beclin-1+/− mice
[110]. In summary, although the usefulness of induction of autophagy
in diabetes is still a controversial issue, themajority of reports implicate
that the restoration of cellular energy household, induction of antioxi-
dant systems and reduction of the detrimental protein synthesis by
the modulation of autophagy-related pathways might serve as thera-
peutic targets in the treatment or prevention of diabetes and its cardiac
complications, once we better understand these processes.
ROS and RNS under pathological conditions may also lead to oxida-
tive DNA injury and overactivation of the nuclear enzyme poly (ADP-
ribose) polymerase 1 (PARP-1), the predominant isoform of the PARP
enzyme family, which normally participates in the regulation of DNA
repair, cell death, metabolism, and inflammatory responses [111].
Following binding to damaged DNA, PARP-1 forms homodimers and
catalyzes the cleavage of its substrate NAD+ into nicotinamide and
ADP-ribose resulting in formation of longbranches of ADP-ribose poly-
mers on target proteins such as histones and PARP-1 itself, which results
in cellular energetic depletion, mitochondrial dysfunction, and ultimate-
ly necrosis. Numerous transcription factors involved in controlling
inflammation such as NFkB, and various signaling molecules have also
been shown to become poly(ADP-ribosylated) by PARP-1 [112]. Thus,
overactivation of PARP-1 due to ROS/RNS formation not only promotes
cell death by ATP andNAD+ depletion, but also stimulates proinflamma-
tory mediator production. PARP inhibitors exerted marked tissue
protective and antiinflammatory effects in preclinical models of ische-
mia–reperfusion injury, endothelial and cardiac dysfunction, circulatory
shock, heart failure and diabetic complications [16,112]. More excitingly
several recent studies have also suggested that PARP-1 and PARP-2
(a minor isoform of the PARP enzyme family) are involved in regulation
of mitochondrial function/biogenesis, and adipogenesis in various organ
systems [113,114], including in the liver, via modulation of NAD+ levels
and consequently sirtuin 1 activity [111,115]. Specifically, PARP inhibi-
tors in rodent models of type I diabetes were very effective in improving
endothelial [116,117] andcardiac function [118], and the PARP activation
from skin biopsies in microvessels positively correlated with the degree
of endothelial dysfunction in prediabetic and diabetic human subjects
[29]. PARP inhibition also prevented the hyperglycemia-induced patho-
logical activation of PKC isoforms, hexosaminase pathway flux, and
AGE formation in vitro, suggesting its key role in regulating pathological
processes promoting the development of all major diabetic complica-
tions [16].
4. Inflammation in diabetic cardiomyopathy
Tschope et al. found using a STZ-induced rat model of type I diabetes
that diabetic cardiomyopathy was characterized by significant increases
in myocardial intercellular adhesion molecule 1 and vascular cell adhe-
sion molecule 1 (ICAM-1 and VCAM-1) expressions, as well as of
beta2-leukocyte-integrins + (CD18+, CD11a+, CD11b+) and cyto-
kine tumor necrosis factor alpha (TNF-α) and interleukin 1 beta (IL-
1β)-expressing infiltrating immune cells. These pro-inflammatory
changes were positively correlated with oxidative stress and decline of
left ventricular function [119]. Interestingly, transgenic activation of
the kallikrein–kinin system inhibited intramyocardial inflammation, en-
dothelial dysfunction and oxidative stress in diabetic hearts [119]. They
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failure by decreasing cardiac inflammation (IL1β, TNFα, and TGFβ
levels) and normalizing MMP activity, leading to attenuated cardiac fi-
brosis in STZ-induced diabetic cardiomyopathy [57]. Using mouse or
ratmodels of type I diabetes they also demonstrated that neutralization
of TNFα [120] or genetic deletion of kinin receptor B [121] attenuated
the development of experimental diabetic cardiomyopathy associated
with a reduction of intramyocardial inflammation and cardiac fibrosis.
They also showed that inhibition of p38 mitogen-activated protein ki-
nase attenuated left ventricular dysfunction by decreasing the level of
myocardial pro-inflammatory cardiac cytokines in amousemodel of di-
abetes mellitus [122], and more recently they suggested that the STZ-
induced diabetic cardiomyopathy is a robust model for investigating
cardiac immune response and LV remodeling processes under diabetic
conditions [123]. Several studies from other groups have also found
similar pro-inflammatory changes in the myocardium of diabetic ro-
dent hearts [37,38,41]. Recently, using type I and II models of diabetes
in mice several studies have also shown activation of the major pro-
inflammatory transcription factor nuclear factor kappa B in diabetic
hearts [37,124] or in human cardiomyocytes or coronary artery endo-
thelial cells exposed to high glucose concentrationswhich triggered en-
hanced ROS/RNS generation [37]. Both studies demonstrated that theLoad
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inflammation also decreased oxidative/nitrative stress, myocardial cell
death, remodeling, and improved diabetes-induced contractile dysfunc-
tion in rodent hearts [37,124]. On the other hand, it has been also re-
ported that the clinically effective drugs (statins [125], RAAS inhibitors
[57], metformin [126], and thiazolidinediones [127]) used in the treat-
ment of metabolic syndrome attenuate the inflammatory response in
diabetes.
Cytokines can attenuate myocyte contractility and viability by
various mechanisms. For example by formation of peroxynitrite,
which was shown to be a major contributor to cytokine-induced myo-
cardial contractile failure [128]. Peroxynitrite is also a major trigger of
apoptosis in cardiomyocytes exposed to various insults in vitro or
in vivo [129,130]. Other proposed mechanisms may involve direct
action on sarcoplasmic reticulum function and on the regulation on
the SR calcium ATPase expression and activity by oxidation/nitration
[10,131]. It is also known, that inflammatory cytokines may regulate
the extracellular matrix composition and dynamics in the heart, which
is a known important determinant of myocardial function [132]. In
agreement with this, inhibition of TNFα signalling with an antibody
for 6 weeks attenuated myocardial inflammation and fibrosis in exper-
imental diabetes [120].Energy Cardiac insult
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art failure. The adverse remodeling and increased peripheral resistance further aggravate
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autophagy and protein quality control is unknown. In other cell types,
autophagosomes are formed in response to a number of environmental
stimuli, including both host- and pathogen-derived molecules, toll-like
receptor ligands or various cytokines [133,134]. In particular, the cyto-
kines IFN-γ, TNF-α, IL-1, IL-2, IL-6 and TGF-β have been shown to in-
duce autophagy, while IGF-1, IL-4, IL-10 and IL-13 have inhibitory
effect. In parallel, autophagy itself can regulate expression of several
cytokines, including IL-1, IL-18, TNF-α, and IFN-γ (for an extensive
review see [134]).
Recent preclinical and clinical studies have also highlighted the role
of endocannabinoids (novel lipid mediators) and their G protein
coupled cannabinoid receptors (CB1 and CB2 receptors) in the regula-
tion of food intake, energy balance, and metabolism (for extensive
review see: [135]). The endocannabinoid system also plays a prominent
role in the pathology of diabetes and obesity [136,137]. We recently
explored the role of endocannabinoids and CB1 receptors in a type I
model of diabetic cardiomyopathy. The diabetic cardiomyopathy was
characterized by myocardial inflammation, increased expression of
CB1, increased oxidative/nitrative stress, β-MHC isoenzyme switch,
AT1R up-regulation, myocardial RAGE and AGE expression/accumula-
tion, MAPK activation, cell death, and cardiac dysfunction (both systolic
and diastolic). Pharmacological inhibition or genetic deletion of CB1 re-
ceptors was associated with attenuated diabetes-induced myocardial
inflammation, decreased MAPK activation, oxidative/nitrative stress,
β-MHC isoenzyme switch, AT1R up-regulation, myocardial RAGE and
AGE expression/accumulation,MAPK activation, and largely diminished
cell death and better preservation of cardiac function [38]. Recent stud-
ies indicate that cannabinoids (especially CB1 agonists) may be impor-
tant inductors of autophagy in preimplantation mouse embryos [138]
and in human epithelial colorectal adenocarcinoma cells (CaCo2)
[139]. Although, the evidences outlined here clearly show that inflam-
mation is one of the key therapeutically important component associat-
edwith diabetic cardiomyopathy, to see if pharmacologicmodulation of
cytokine as well as cannabinoid signalling and thereby autophagy has
therapeutic potential, further experimental studies are required.
5. Conclusions
Despite our accumulating knowledge based on preclinical reports,
the treatment of diabetic cardiomyopathy is still largely symptomatic
once it fully develops, which inevitably progresses to heart failure (see
Fig. 3 for the progression of diabetic cardiomyopathy to heart failure).
Therefore, an early diagnosis of this condition and rigorous glycemic
control is very important to try to slow down the progression of the
disease as much as possible. From preclinical and human studies it has
become clear that oxidative/nitrative stress and inflammation are
central components in triggering and driving the pathological processes
associated with diabetic cardiomyopathy and other cardiovascular
complications. However, recognizing the largely disappointing results
of clinical trials with global antioxidants in diabetes, it is essential to
keep in mind the necessity of more thorough understanding the com-
plex interplay of oxidative/nitrosative stress with pro-inflammatory,
metabolic and cell death signaling pathways, the specificity of these
processes, and their temporal– spatial relationship.
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